Plain-English translation of NCT04436978 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether a short-term combination of aspirin and a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) followed by edoxaban is safer and just as effective as the standard approach for people with both atrial fibrillation and a newly placed heart stent. The current standard treatment uses three blood thinners together, which works well to prevent clots but causes more bleeding. The researchers believe that using the new treatment combination might reduce bleeding risk while still protecting your stent.
People with both irregular heartbeat and heart stents currently receive three blood-thinning medications at once, which significantly increases the risk of dangerous bleeding. This trial exists to find out whether reducing to two medications for the first month—then switching to one long-term medication—can prevent clots and stent problems while causing fewer bleeding complications.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to one of two treatment groups. Both groups will take blood-thinning medications, but in different combinations and for different lengths of time. In the first month after your stent, one group takes aspirin plus another blood thinner, while the other group follows standard guidelines. After 30 days, both groups switch to the same long-term medication (edoxaban) plus another blood thinner. The trial will track you over time to monitor whether your stent remains open, whether you have any bleeding problems, and other heart-related events.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
Belgium